PGEN — Precigen, Inc.

Summary of Precigen, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q4 2025 net product revenue was $3.4 million, with total revenue for the year reaching $9.7 million, a 149% increase from $3.2 million in 2024. The revenue growth was primarily driven by the launch of Papzimia in November 2025.
• Net Loss: The net loss attributable to common shareholders was $429.6 million, or $1.37 per share, which included significant noncash items related to preferred stock and warrants.
• Cash Position: As of year-end, the company had $100.4 million in cash, cash equivalents, and investments, expected to fund operations through cash flow breakeven anticipated in 2026.

2. Strategic Updates and Business Highlights

• Product Launch: The commercial launch of Papzimia for adult recurrent respiratory papillomatosis (RRP) began in Q4 2025, marking a transition from an R&D-focused company to a revenue-generating biotech.
• Market Acceptance: Strong physician and patient interest has been noted, with over 300 patients in the support hub and approximately 215 million lives covered by payer agreements.
• Clinical Data: Papzimia received FDA approval with a broad label, supported by robust clinical data demonstrating unmatched efficacy and durability in treating RRP.
• Expansion Plans: The company is advancing plans for a pediatric RRP clinical trial and has submitted a marketing authorization application to the EMA for Papzimia.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Projection: Based on current commercial activity, Precigen anticipates Q1 2026 revenues will exceed $18 million, reflecting strong uptake of Papzimia.
• Long-term Strategy: The company does not plan to provide regular revenue guidance but will focus on key indicators for assessing launch progress.

4. Challenges and Points of Concern

• High Net Loss: The substantial net loss raises concerns regarding profitability and financial sustainability, although nonrecurring items contributed significantly to this figure.
• Operational Risks: The transition from an R&D to a commercial model presents operational challenges, including ensuring patient access and reimbursement processes.
• Market Competition: While Papzimia has established itself as a new standard of care, future competitive pressures from other therapies in the RRP space could impact market share.

5. Notable Q&A Insights

• Patient Flow and Reimbursement: Executives indicated that the conversion of patients from the support hub to receiving reimbursed treatment is progressing well, aided by the upcoming permanent J-code for billing.
• Community Adoption: There is a positive trend in community site adoption, with strategies in place to facilitate logistics and reduce barriers for these practices.
• Payer Mix: Approximately 60-65% of the payer mix is commercial, with the remainder from Medicare and Medicaid, aligning with earlier expectations.
• Gross to Net Guidance: The company anticipates a gross-to-net ratio in the high teens to low twenties for the balance of the year.

Overall, Precigen, Inc. is experiencing significant momentum with the launch of Papzimia, supported by strong early revenue growth and positive market reception, while also facing challenges related to high operating losses and the complexities of transitioning to a commercial entity.